quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:05:00·85d
PRRelease
CRISPR Therapeutics AG logo
Editas Medicine Inc. logo
Intellia Therapeutics Inc. logo

Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine

CRSP· CRISPR Therapeutics AGEDIT· Editas Medicine Inc.NTLA· Intellia Therapeutics Inc.
Health Care
Original source

Companies

  • CRSP
    CRISPR Therapeutics AG
    Health Care
  • EDIT
    Editas Medicine Inc.
    Health Care
  • NTLA
    Intellia Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 2NTLAUpdateWilliam Blair-
  • Nov 12NTLAUpdateWolfe Research-
  • Nov 11NTLAUpdateEvercore ISI$8.00
  • Nov 7NTLAUpdateAnalyst$5.00
  • Oct 28NTLAUpdateRBC Capital Mkts$14.00
  • Oct 28NTLAUpdateBernstein-

Related

  • SEC2d
    SEC Form DEFA14A filed by CRISPR Therapeutics AG
  • SEC2d
    SEC Form DEF 14A filed by CRISPR Therapeutics AG
  • SEC13d
    SEC Form 8-K filed by Intellia Therapeutics Inc.
  • PR15d
    The Credibility Filter Wall Street Uses to Sort Biotech Winners
  • SEC16d
    Editas Medicine Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
  • PR16d
    CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
  • PR20d
    Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • SEC21d
    SEC Form PRE 14A filed by CRISPR Therapeutics AG
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022